Department of Microbiology and Immunology
Dr. Li’s Work featured in May 2017 Online Cover of Science Immunology and EurekAlert!
Cancers adapt to single therapies, making combination therapies the approach of choice. Complementary therapies that decrease immunosuppression may boost the efficacy of immunotherapies. Now, the laboratory of Dr. Zihai Li reports that targeting platelets improves adoptive T cell therapy of multiple cancers. They found that transforming growth factor β (TGFβ) from platelets decrease T cell function largely through the expression of the TGFβ-docking receptor, GARP. These data suggest that combining immunotherapy with platelet inhibitors may be a complementary approach to cancer therapy. This work, highlighted in a EurekAlert! Public Release, was first published in Science Immunology. In fact, it is featured in the journal’s May 2017 Online Cover (see image below).